Is Radiopharm Theranostics Ltd (RADX) Halal?
Shariah Screening — 5 Standards
Based on financial data from June 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 74.0% / 30% | 26.4% / 30% | 24.45% / 5% | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 74.0% / 33% | 26.4% / 33% | 24.45% / 5% | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 33.7% / 33% | 12.0% / 33% | 24.45% / 5% | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 74.0% / 33% | 26.4% / 33% | 24.45% / 5% | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 33.7% / 33% | 12.0% / 50% | 24.45% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -136.5% | |
| Operating Margin | -423.8% | |
| Net Margin | -286.2% | |
| Return on Equity (ROE) | -92.1% | |
| Return on Assets (ROA) | -28.3% |
Cash Flow & Balance Sheet
| Free Cash Flow | -$37M |
| Current Ratio | 3.0 |
| Total Assets | $86M |
Price & Trading
| Last Close | $4.25 |
| 50-Day MA | $4.88 |
| 200-Day MA | $5.17 |
| Avg Volume | 53K |
| Beta | 0.9 |
|
52-Week Range
$3.50
| |
About Radiopharm Theranostics Ltd (RADX)
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Radiopharm Theranostics Ltd (RADX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Radiopharm Theranostics Ltd is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Radiopharm Theranostics Ltd's debt ratio?
Radiopharm Theranostics Ltd's debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Radiopharm Theranostics Ltd's key financial metrics?
Radiopharm Theranostics Ltd has a market capitalization of $34M, and revenue of $4M. The company maintains a gross margin of -136.5% and a net margin of -286.2%. Return on equity stands at -92.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.